Ekso Bionics (EKSO) Trading Up 7.4%

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) were up 7.4% during mid-day trading on Friday . The stock traded as high as $2.05 and last traded at $2.02. Approximately 1,361,300 shares changed hands during trading, an increase of 30% from the average daily volume of 1,047,263 shares. The stock had previously closed at $1.88.

Several analysts recently issued reports on EKSO shares. Zacks Investment Research downgraded Ekso Bionics from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. ValuEngine raised Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.

The company has a market cap of $121.01, a P/E ratio of -2.16 and a beta of 2.01. The company has a current ratio of 6.09, a quick ratio of 5.73 and a debt-to-equity ratio of 0.18.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. sell-side analysts forecast that Ekso Bionics Holdings, Inc. will post -0.81 EPS for the current year.

In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.32% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. National Planning Corp grew its holdings in Ekso Bionics by 122.2% during the 3rd quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after buying an additional 286,492 shares in the last quarter. Intellectus Partners LLC grew its holdings in Ekso Bionics by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. Carl Domino Inc grew its holdings in Ekso Bionics by 125.2% during the 3rd quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after buying an additional 102,734 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Ekso Bionics by 32.9% during the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares in the last quarter. Institutional investors and hedge funds own 6.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ekso Bionics (EKSO) Trading Up 7.4%” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2018/01/14/ekso-bionics-ekso-trading-up-7-4.html.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit